By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Celera reported after the close of the market Wednesday that its fourth-quarter revenues declined 15 percent due to a drop in its lab services receipts.

The Alameda, Calif.-based molecular diagnostics firm brought in total revenues of $40 million for the three-month period ended Dec. 26, 2009, down from revenues of $47.3 million for the fourth quarter of 2008. The results edged analysts' consensus estimate of $39.6 million for the quarter.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: factors influencing retrotransposon integration sites, and more.

A bioethicist argues for the responsible use of germline gene editing.

Some breweries are using DNA-based testing to determine whether unwanted bacteria are affecting their beers, The Verge reports.

Standardized N-of-1 trials will be needed to test out personalized medicines, writes Nicholas Schork from the J. Craig Venter Institute at Nature.